A randomized, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL).

Trial Profile

A randomized, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL).

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs NT 100 (Primary)
  • Indications Spontaneous abortion
  • Focus Therapeutic Use
  • Acronyms RESPONSE
  • Sponsors Nora Therapeutics
  • Most Recent Events

    • 01 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 14 Jul 2015 Planned End Date changed from 1 Feb 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.
    • 14 Jul 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top